JP Morgan Chase’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,461,262
| Closed | -$76.7M | – | 6190 |
|
|
2020
Q3 | $76.7M | Buy |
1,461,262
+1,226,776
| +523% | +$50.8M | 0.01% | 790 |
|
|
2020
Q2 | $7.8M | Buy |
234,486
+40,262
| +21% | +$1.28M | ﹤0.01% | 2099 |
|
|
2020
Q1 | $5.28M | Sell |
194,224
-66,598
| -26% | -$1.85M | ﹤0.01% | 2217 |
|
|
2019
Q4 | $5.15M | Buy |
260,822
+59,249
| +29% | +$947K | ﹤0.01% | 2651 |
|
|
2019
Q3 | $2.61M | Sell |
201,573
-59,128
| -23% | -$714K | ﹤0.01% | 3232 |
|
|
2019
Q2 | $3.22M | Sell |
260,701
-19,873
| -7% | -$264K | ﹤0.01% | 3017 |
|
|
2019
Q1 | $4.08M | Buy |
280,574
+20,882
| +8% | +$267K | ﹤0.01% | 2757 |
|
|
2018
Q4 | $2.87M | Sell |
259,692
-22,598
| -8% | -$315K | ﹤0.01% | 3008 |
|
|
2018
Q3 | $7.42M | Sell |
282,290
-93,062
| -25% | -$2.52M | ﹤0.01% | 2444 |
|
|
2018
Q2 | $7.68M | Sell |
375,352
-308,931
| -45% | -$6.63M | ﹤0.01% | 2352 |
|
|
2018
Q1 | $12.4M | Sell |
684,283
-97,617
| -12% | -$1.63M | ﹤0.01% | 1868 |
|
|
2017
Q4 | $10.9M | Buy |
781,900
+153,669
| +24% | +$2.08M | ﹤0.01% | 2053 |
|
|
2017
Q3 | $12M | Sell |
628,231
-18,786
| -3% | -$314K | ﹤0.01% | 1852 |
|
|
2017
Q2 | $10.9M | Buy |
647,017
+10,273
| +2% | +$156K | ﹤0.01% | 1902 |
|
|
2017
Q1 | $8.5M | Buy |
636,744
+251,159
| +65% | +$3.93M | ﹤0.01% | 2043 |
|
|
2016
Q4 | $5.8M | Sell |
385,585
-5,040
| -1% | -$66.6K | ﹤0.01% | 2333 |
|
|
2016
Q3 | $4.57M | Buy |
390,625
+5,575
| +1% | +$65.5K | ﹤0.01% | 2315 |
|
|
2016
Q2 | $4.16M | Buy |
385,050
+3,175
| +0.8% | +$32.8K | ﹤0.01% | 2408 |
|
|
2016
Q1 | $3.53M | Buy |
381,875
+156,725
| +70% | +$1.69M | ﹤0.01% | 2406 |
|
|
2015
Q4 | $3.34M | Sell |
225,150
-24,600
| -10% | -$412K | ﹤0.01% | 2461 |
|
|
2015
Q3 | $4.1M | Sell |
249,750
-286,075
| -53% | -$5.86M | ﹤0.01% | 2347 |
|
|
2015
Q2 | $12.2M | Buy |
535,825
+184,400
| +52% | +$3.67M | ﹤0.01% | 1772 |
|
|
2015
Q1 | $5.34M | Buy |
+351,425
| New | +$4.57M | ﹤0.01% | 2304 |
|
|
2013
Q4 | – | Sell |
-89,912
| Closed | -$1.29M | – | 4314 |
|
|
2013
Q3 | $1.29M | Sell |
89,912
-25,310
| -22% | -$387K | ﹤0.01% | 3106 |
|
|
2013
Q2 | $1.74M | Buy |
+115,222
| New | +$1.52M | ﹤0.01% | 2897 |
|
JP Morgan Chase's MNTA Position: Q4 2020 in Review
JP Morgan Chase sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 1,461,262 shares — an estimated $76.7M sold.
JP Morgan Chase first reported a position in MNTA in Q2 2013 and held it in 25 quarters. The position peaked at $76.7M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- JP Morgan Chase reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- JP Morgan Chase sold 1,461,262 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $76.7M.
- JP Morgan Chase first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
- JP Morgan Chase's Momenta Pharmaceuticals, Inc. position peaked at $76.7M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on JP Morgan Chase's 13F filing for Q4 2020, filed 11 Feb 2021.